Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: SynKIR-310 for Relapsed/Refractory B-NHL [Phase 1]
Phase 1 trial update for SynKIR-310 in relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma [Phase 1]
This Phase 1 clinical trial update investigates adding glofitamab to alternating R-CHOP/R-DHAP chemotherapy in previously untreated mantle c…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies [Phase 1, Phase 2]
AstraZeneca is evaluating AZD0486 as a monotherapy or in combination with other anticancer agents for mature B-cell malignancies in Phase 1/…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial evaluating a three-drug regimen (alisertib, bortezomib, and rituximab) in patients with relapsed or refractory mantle…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Long-term Extension Study of PCI-32765 (Ibrutinib) [Phase 3]
Phase 3 long-term extension study of ibrutinib (PCI-32765) in chronic lymphocytic leukemia/small lymphocytic lymphoma and other B-cell malig…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma [Phase 1]
A Phase 1 clinical trial is evaluating the combination of ibrutinib and palbociclib in patients with previously treated mantle cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
This document provides a long-term follow-up update on allogeneic gamma delta CAR T cell therapy. The trial covers several B-cell lymphoma i…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma [Phase 2]
This document reports an ongoing Phase II trial assessing the combination of palbociclib and ibrutinib in mantle cell lymphoma, with the stu…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma [Phase 1, Phase 2]
Genmab-sponsored first-in-human trial in relapsed/refractory B-cell lymphomas spans Phase 1/2 and is currently active/not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T [Phase 1]
This clinical trial update reports long-term follow-up results from a Phase 1 study of CLBR001 CAR-T cells in relapsed/refractory B-cell lym…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain [Phase 2]
Acalabrutinib is being studied in combination with R-CHOP for previously untreated mantle cell lymphoma in Spain in a Phase 2 trial that is …
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Expanded access study for brexucabtagene autoleucel (Tecartus) for mantle cell lymphoma and acute lymphoblastic leukemia is currently availa…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma [Phase 3]
Phase 3 clinical trial comparing continuous versus intermittent zanubrutinib in older patients with previously untreated mantle cell lymphom…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating pacritinib in combination with a BTK inhibitor for relapsed or refractory mantle cell lymphoma is curren…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]
A Phase 1 study of CLIC-2201 for relapsed/refractory B-cell malignancies is currently recruiting. The conditions covered include various B-c…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma [Phase 3]
Phase 3 clinical trial to compare glofitamab as a single agent against investigator's choice in relapsed/refractory mantle cell lymphoma is …
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study update for VAY736 in non-Hodgkin lymphoma shows the trial status as terminated, evaluating VAY736 alone and in combination wit…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL [Phase 2]
Phase 2 open-label randomized trial evaluating the combination of pirtobrutinib and Brexucabtagene Autoleucel in relapsed/refractory mantle …
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating memory-enriched T cells following stem cell transplantation for recurrent B-cell non-Hodgkin lymphomas; the study i…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma [Phase 3]
A Phase III randomized trial evaluating orelabrutinib plus R-CHOP versus R-CHOP alone in treatment-naïve mantle cell lymphoma has completed.
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) [Phase 1, Phase 2]
A Phase 1/2 clinical trial of SENTRY-CD19, a CD19-targeted gene therapy, in multiple CD19-positive hematologic malignancies is currently rec…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating the combination of glofitamab and lenalidomide in patients with mantle cell lymphoma.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies [Phase 1]
Phase 1 clinical trial evaluating Sonrotoclax (BGB-11417), a Bcl-2 inhibitor, in participants with mature B-cell malignancies. The study is …
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL [Phase 2]
Phase 2 trial evaluating ibrutinib in combination with rituximab for indolent mantle cell lymphoma is currently active and not recruiting.
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy [Phase 2]
Phase 2 trial evaluating the combination of Sonrotoclax and Zanubrutinib in relapsed/refractory Mantle Cell Lymphoma patients who are planne…